Merck, Inc.
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05450198
- Locations
- 🇺🇸
AXIS Clinicals ( Site 0029), Dilworth, Minnesota, United States
🇨🇦Innovaderm Research Inc. ( Site 0019), Montréal, Quebec, Canada
🇺🇸Progressive Clinical Research ( Site 0022), San Antonio, Texas, United States
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT05446870
- Locations
- 🇨🇳
Changhua Christian Hospital-Obstetrics and Gynecology ( Site 1203), Changhua County, Changhua, Taiwan
🇪🇸Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1101), Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1104), Madrid, Madrid, Comunidad De, Spain
Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2663
- Registration Number
- NCT05425732
- Locations
- 🇺🇸
Baptist Health Center For Clinical Research ( Site 0019), Little Rock, Arkansas, United States
🇺🇸Millennium Clinical Trials ( Site 0013), Simi Valley, California, United States
🇺🇸Alliance for Multispecialty Research, LLC ( Site 0015), Coral Gables, Florida, United States
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)
- Conditions
- Interventions
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 717
- Registration Number
- NCT05420961
- Locations
- 🇮🇱
Maccabi Health Services - Holon ( Site 0305), Holon, Israel
🇮🇱Maccabi Healthcare Services ( Site 0306), Jerusalem, Israel
🇮🇱Meir Medical Center ( Site 0301), Kfar Saba, Israel
A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 53
- Registration Number
- NCT05406440
- Locations
- 🇺🇸
California Clinical Trials Medical Group managed by PAREXEL ( Site 0002), Glendale, California, United States
🇺🇸Hassman Research Institute Marlton Site ( Site 0003), Marlton, New Jersey, United States
🇺🇸Collaborative Neuroscience Research, LLC ( Site 0004), Garden Grove, California, United States
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
- Conditions
- Interventions
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05406401
- Locations
- 🇰🇷
Seoul National University Hospital ( Site 0201), Seoul, Korea, Republic of
🇰🇷Samsung Medical Center ( Site 0200), Seoul, Korea, Republic of
🇨🇦BC Cancer Victoria-Clinical Trials Unit ( Site 0105), Victoria, British Columbia, Canada
A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 27
- Registration Number
- NCT05394350
- Locations
- 🇨🇭
Cantonal Hospital St.Gallen ( Site 0403), st.Gallen, Sankt Gallen, Switzerland
🇨🇭Ospedale Regionale Bellinzona e Valli ( Site 0400), Bellinzona, Ticino, Switzerland
🇩🇰Rigshospitalet ( Site 0500), Copenhagen, Hovedstaden, Denmark
Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
- Conditions
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 313
- Registration Number
- NCT05393037
- Locations
- 🇨🇱
Universidad de Chile - Hospital Clínico Universidad de Chile ( Site 0107), Santiago, Region M. De Santiago, Chile
🇿🇦Be Part Yoluntu Centre ( Site 0902), Paarl, Western Cape, South Africa
🇿🇦Josha Research ( Site 0900), Bloemfontein, Free State, South Africa
A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT05386758
- Locations
- 🇺🇸
Advanced Pharma CR, LLC ( Site 0004), Miami, Florida, United States
🇺🇸Velocity Clinical Research, Hallandale Beach ( Site 0005), Hallandale Beach, Florida, United States
🇺🇸Genesis Clinical Research, LLC ( Site 0003), Tampa, Florida, United States
A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT05386589
- Locations
- 🇺🇸
Research Centers of America ( Hollywood ) ( Site 0002), Hollywood, Florida, United States
🇺🇸Clinical Pharmacology of Miami ( Site 0003), Miami, Florida, United States
🇺🇸Thomas Jefferson University - Pharmacology and Experimental Therapeutics ( Site 0001), Philadelphia, Pennsylvania, United States